BPC-157 Is Legal Again in 2026: What the FDA Reclassification Actually Means

What happened on April 22, 2026

On April 22, 2026, the FDA formally reversed its 2024 decision that had removed BPC-157 and 13 other peptides from the list of substances that compounding pharmacies could use. The reversal came after significant pushback from the medical community, patient advocacy groups, and following a formal FDA advisory committee review convened under the direction of HHS Secretary RFK Jr.

The practical effect: compounding pharmacies can once again legally prepare BPC-157 for individual patients under a valid physician prescription. Patients who had lost access to compounded BPC-157 after the 2024 crackdown can now legally access it again through a licensed clinic.

Which 14 peptides were reclassified?

The April 2026 reclassification restored compounding eligibility for the following peptides:

1. 1BPC-157 (Body Protection Compound-157) - tendon, ligament, gut healing
2. 2TB-500 (Thymosin Beta-4) - soft tissue repair, inflammation
3. 3CJC-1295 - growth hormone secretagogue
4. 4Ipamorelin - GH secretagogue, sleep, recovery
5. 5Sermorelin - GH secretagogue (this had remained available at many compounders but the clarification helps)
6. 6GHRP-2 - growth hormone releasing peptide
7. 7GHRP-6 - growth hormone releasing peptide
8. 8Hexarelin - GH secretagogue
9. 9Epithalon (Epitalon) - longevity, anti-aging peptide
10. 10GHK-Cu (Copper Peptide) - skin, hair, anti-aging
11. 11Selank - anxiety, cognitive function
12. 12Semax - cognitive function, neuroprotection
13. 13PT-141 (Bremelanotide) - sexual health (some compounders had continued offering this)
14. 14AOD-9604 - fat metabolism fragment

Note: This list reflects the reclassification as reported in April 2026. Individual pharmacy formularies may vary, and physicians may have state-specific prescribing restrictions.

What this does NOT change

The reclassification does not make peptides available over the counter or without a prescription. The framework is:

• Physician prescription required - a licensed MD, DO, NP, or PA must prescribe
• FDA-registered 503A or 503B compounding pharmacy - the pharmacy must be operating under proper oversight
• Individual patient use - compounded peptides cannot be manufactured in bulk for resale

Buying BPC-157 from research chemical websites, overseas vendors, or without a valid prescription remains illegal and carries significant quality and legal risks.

Why this matters: what changed in 2024

In 2024, the FDA classified BPC-157 and several other peptides as Category 2 substances (bulk substances that may not be used in compounding). This effectively ended the ability of licensed compounding pharmacies to prepare these peptides for patients.

The practical impact was significant: clinics that had offered these peptides were forced to stop, and patients who had been on established protocols lost access. The move was controversial because:

• BPC-157 had been used clinically for years with a strong safety record
• No equivalent FDA-approved alternative existed for many of its uses
• The decision was seen as inconsistent with how similarly-situated substances were treated

The April 2026 reversal addressed these concerns and restored patient access through the regulated compounding pathway.

How to access BPC-157 now

The process for accessing compounded BPC-157 is the same as for any prescription medicine:

1. Physician consultation

A licensed physician assesses your condition and determines whether BPC-157 is appropriate. This can be done via telehealth in most states. Common use cases: tendon and ligament injuries, post-surgical recovery, gut conditions (leaky gut, IBS), chronic inflammation.

2. Prescription issued

The physician writes a prescription for a specific dose, form, and quantity. BPC-157 is typically available as:

• Subcutaneous injection (most common for musculoskeletal use)
• Oral capsules (primarily for gut conditions)
• Nasal spray

3. Compounding pharmacy fills the prescription

The prescription is sent to an FDA-registered 503A or 503B compounding pharmacy. The pharmacy prepares the peptide and ships directly to the patient.

4. Follow-up

Most protocols run 4-8 weeks with a follow-up to assess response.

What to look for in a clinic

Post-reclassification, a significant number of clinics are re-adding BPC-157. When evaluating clinics:

• Confirm the physician holds a valid license in your state
• Ask which compounding pharmacy they use and whether it's FDA-registered
• Confirm they will provide a valid prescription (not just sell product directly)
• Ask about their experience with BPC-157 protocols specifically

Browse BPC-157 clinics near you - filter by state or telehealth to find verified providers.

---

Related guides

BPC-157 vs TB-500 - which is right for your recovery? - What peptides are legal in the US in 2026? - How to find a peptide clinic near you